Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP

Wojdała, Anna Lidia; Bellomo, Giovanni; Gaetani, Lorenzo; Toja, Andrea; Chipi, Elena; Shan, Dandan; Chiasserini, Davide; Parnetti, Lucilla

doi:10.1016/j.nbd.2023.106356

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We examined the AD biomarkers Aβ -5 of 8 orthopedic surgery. As has been shown previously, 43 we found moderate correlations (range 0.42-0.60) between CSF and plasma values for p-Tau 181 , GFAP and NfL, suggesting that plasma levels of each of these biomarkers are closely associated with their CSF levels.…”

Section: Discussionsupporting

confidence: 86%

“…We examined the AD biomarkers Aβ 42 , Aβ 40 , and p‐Tau 181 , plus the neural injury marker NFL and astrocyte activation marker GFAP in CSF and plasma in a cohort of older adults undergoing elective orthopedic surgery. As has been shown previously, 43 we found moderate correlations (range 0.42–0.60) between CSF and plasma values for p‐Tau 181 , GFAP and NfL, suggesting that plasma levels of each of these biomarkers are closely associated with their CSF levels. Moreover, GFAP also correlated with all other biomarkers between CSF and plasma.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Biomarkers of neurodegeneration and neural injury as potential predictors for delirium

Fong,

Vasunilashorn,

Kivisäkk

et al. 2023

Int J Geriat Psychiatry

View full text Add to dashboard Cite

ObjectivesDetermine if biomarkers of Alzheimer's disease and neural injury may play a role in the prediction of delirium risk.MethodsIn a cohort of older adults who underwent elective surgery, delirium case‐no delirium control pairs (N = 70, or 35 matched pairs) were matched by age, sex and vascular comorbidities. Biomarkers from CSF and plasma samples collected prior to surgery, including amyloid beta (Aβ)42, Aβ40, total (t)‐Tau, phosphorylated (p)‐Tau181, neurofilament‐light (NfL), and glial fibrillary acid protein (GFAP) were measured in cerebrospinal fluid (CSF) and plasma using sandwich enzyme‐linked immunosorbent assays (ELISAs) or ultrasensitive single molecule array (Simoa) immunoassays.ResultsPlasma GFAP correlated significantly with CSF GFAP and both plasma and CSF GFAP values were nearly two‐fold higher in delirium cases. The median paired difference between delirium case and control without delirium for plasma GFAP was not significant (p = 0.074) but higher levels were associated with a greater risk for delirium (odds ratio 1.52, 95% confidence interval 0.85, 2.72 per standard deviation increase in plasma GFAP concentration) in this small study. No matched pair differences or associations with delirium were observed for NfL, p‐Tau 181, Aβ40 and Aβ42.ConclusionsThese preliminary findings suggest that plasma GFAP, a marker of astroglial activation, may be worth further investigation as a predictive risk marker for delirium.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 86%

Biomarkers of neurodegeneration and neural injury as potential predictors for delirium

Fong,

Vasunilashorn,

Kivisäkk

et al. 2023

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…CSF GFAP increased with plaque deposition ( Benedet et al, 2021 ), and it could be used to predict the progression from MCI to AD ( Cicognola et al, 2021 ). In addition, studies found that CSF GFAP can effectively differentiate healthy population from preclinical ADs ( Wojdała et al, 2023 ). Plasma GFAP is considered as an early biomarker for Aβ pathology, but it is not related with tau pathology ( Pereira et al, 2021 ).…”

Section: Biomarkers Of Neuroinflammationmentioning

confidence: 99%

Biofluid biomarkers for Alzheimer’s disease

Wang,

Xie,

Zheng

et al. 2024

Front. Aging Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease, with a complex pathogenesis and an irreversible course. Therefore, the early diagnosis of AD is particularly important for the intervention, prevention, and treatment of the disease. Based on the different pathophysiological mechanisms of AD, the research progress of biofluid biomarkers are classified and reviewed. In the end, the challenges and perspectives of future research are proposed.

show abstract

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

Verberk,

Jutte,

Kingma

et al. 2024

Alzheimer's & Dementia

View full text Add to dashboard Cite

INTRODUCTIONWe developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P‐)tau181, amyloid‐beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).METHODSWe measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach.RESULTSP‐tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre‐dementia stages, AUC = 87%–89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%–76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand‐alone biomarker results and density plots to visualize the biomarker results combined.DISCUSSIONOur multimarker blood test interpretation tool is ready for testing in real‐world clinical dementia settings.Highlights We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P‐tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.

show abstract

Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP

Cited by 4 publications

References 30 publications

Biomarkers of neurodegeneration and neural injury as potential predictors for delirium

Biomarkers of neurodegeneration and neural injury as potential predictors for delirium

Biofluid biomarkers for Alzheimer’s disease

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

Contact Info

Product

Resources

About